이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Paradigm Biopharmaceuticals 관리

관리 기준 확인 2/4

Paradigm Biopharmaceuticals' CEO는 Paul Rennie, Jan2014 에 임명되었습니다 의 임기는 10.42 년입니다. 총 연간 보상은 A$ 1.95M, 30.9% 로 구성됩니다. 30.9% 급여 및 69.1% 보너스(회사 주식 및 옵션 포함). 는 A$ 2.05M 가치에 해당하는 회사 주식의 2.65% 직접 소유합니다. 2.05M. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 3.7 년입니다.

주요 정보

Paul Rennie

최고 경영자

AU$1.9m

총 보상

CEO 급여 비율	30.9%
CEO 임기	10.4yrs
CEO 소유권	2.7%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

CEO 보상 분석

Paul Rennie 의 보수는 Paradigm Biopharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	n/a	n/a	-AU$69m
Sep 30 2023	n/a	n/a	-AU$60m
Jun 30 2023	AU$2m	AU$602k	-AU$52m
Mar 31 2023	n/a	n/a	-AU$48m
Dec 31 2022	n/a	n/a	-AU$44m
Sep 30 2022	n/a	n/a	-AU$42m
Jun 30 2022	AU$1m	AU$219k	-AU$39m
Mar 31 2022	n/a	n/a	-AU$40m
Dec 31 2021	n/a	n/a	-AU$41m
Sep 30 2021	n/a	n/a	-AU$37m
Jun 30 2021	AU$1m	AU$510k	-AU$34m
Mar 31 2021	n/a	n/a	-AU$31m
Dec 31 2020	n/a	n/a	-AU$28m
Sep 30 2020	n/a	n/a	-AU$20m
Jun 30 2020	AU$632k	AU$462k	-AU$12m
Mar 31 2020	n/a	n/a	-AU$14m
Dec 31 2019	n/a	n/a	-AU$16m
Sep 30 2019	n/a	n/a	-AU$16m
Jun 30 2019	AU$1m	AU$420k	-AU$16m
Mar 31 2019	n/a	n/a	-AU$11m
Dec 31 2018	n/a	n/a	-AU$7m
Sep 30 2018	n/a	n/a	-AU$7m
Jun 30 2018	AU$573k	AU$380k	-AU$6m
Mar 31 2018	n/a	n/a	-AU$6m
Dec 31 2017	n/a	n/a	-AU$5m
Sep 30 2017	n/a	n/a	-AU$5m
Jun 30 2017	AU$517k	AU$350k	-AU$4m

보상 대 시장: Paul 의 총 보상 ($USD 1.30M )은 Australian 시장( $USD 298.77K ).

보상과 수익: 회사가 수익성이 없는 동안 Paul 의 보상이 증가했습니다.

CEO

Paul Rennie (65 yo)

10.4yrs

테뉴어

AU$1,947,027

보상

Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, served as Independent Non-Executive Chairman at NeuroScientific Biopharmaceuticals Limited since June 21, 2021 until November 23, 2022, was it...

리더십 팀

이름	위치	테뉴어	보상	소유권
Paul Rennie	Founder	10.4yrs	AU$1.95m	2.65% A$ 2.3m
Donna Skerrett	Chief Medical Officer and Executive Director	1.9yrs	AU$1.51m	0.31% A$ 268.1k
Abby Macnish Niven	Interim Company Secretary & Interim CFO	1.8yrs	데이터 없음	데이터 없음
Ravi Krishnan	Chief Scientific Officer	8.8yrs	데이터 없음	데이터 없음
Simon White	Director of Investor Relations	no data	데이터 없음	데이터 없음
Michael Imperiale	Global Head of Drug Safety & MPS	4yrs	데이터 없음	데이터 없음
Beverley Huttmann	Commercial Head	3.7yrs	데이터 없음	데이터 없음
Michelle Coffey	Global Head of Regulatory Affairs	no data	데이터 없음	데이터 없음
Mukesh Ahuja	Global Clinical Head of OA	no data	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

경험이 풍부한 관리: PAR 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paul Rennie	Founder	10.1yrs	AU$1.95m	2.65% A$ 2.3m
Donna Skerrett	Chief Medical Officer and Executive Director	3.9yrs	AU$1.51m	0.31% A$ 268.1k
Amos Meltzer	Independent & Non-Executive Director	3.5yrs	AU$88.40k	데이터 없음
Matthew Fry	Director	less than a year	데이터 없음	0.31% A$ 262.1k

3.7yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: PAR 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

Paradigm Biopharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Founder recently bought AU$76k worth of stock

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Recent updates

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

New 90-day low: AU$2.38

New 90-day low: AU$2.44

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Paradigm Biopharmaceuticals Ltd Receives the Written Response from the Type-C meeting with the US Food and Drug Administration (FDA) regarding Zilosul® for the Treatment of Osteoarthritis

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director

New 90-day high: AU$3.13

Paradigm Biopharmaceuticals Limited Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating PPS in Mucopulysaccharidoses Type-1

Paradigm Biopharmaceuticals Limited Adds Senior Executives to its Team

Paradigm Biopharmaceuticals Ltd Clear Path Towards Zilosul's Oa Phase 3 Clinical Trial and Product Registration in Europe